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Inflammation has been suggested to play an important role in onset and progression of 
prostate cancer (PCa). Histological analysis of prostatectomy specimens has revealed 
focal inflammation in early stage lesions of this malignancy. We addressed the role of 
inflammatory stimuli in the release of PCa-specific, tumor-derived soluble factors (PCa-
TDSFs) already reported to be mediators of PCa morbidity, such as indoleamine 2,3-diox-
ygenase (IDO) and interleukin (IL)-6. Inflammation-driven production and functions of 
PCa-TDFSs were tested “in vitro” by stimulating established cell lines (CA-HPV-10 and 
PC3) with IFN-γ or TNF-α. Expression of genes encoding IDO, IL-6, IFN-γ, TNF-α, and 
their receptors was investigated in tumor tissues of PCa patients undergoing radical 
prostatectomy, in comparison with benign prostatic hyperplasia (BPH) specimens. IFN-γ 
and TNF-α-treatment resulted in the induction of IDO and IL-6 gene expression and 
release in established cell lines, suggesting that the elicitation of PCa-TDSFs by these 
cytokines might contribute to progression of cancer into an untreatable phenotype. An 
analysis based on timing of biochemical recurrence revealed the prognostic value of IDO 
but not IL-6 gene expression in predicting recurrence-free survival in patients (RFS) with 
PCa. In addition, a urine-based mRNA biomarker study revealed the diagnostic potential 
of IDO gene expression in urines of men at risk of PCa development.
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inTrODUcTiOn
Chronic inflammation is considered an “enabling” characteristic of human cancers (1), although its 
prognostic significance in malignancies of different histological origin is debated (2). Histological 
analysis of prostate cancer (PCa) samples consistently indicates that inflammation might play 
a key role in the progression of this tumor (3). PCa is more frequent in demographic groups 
with high prevalence of prostatic inflammation (4), with a higher risk for obese men (5, 6). In 
Abbreviations: PCa, prostate cancer; BPH, benign prostatic hyperplasia; TUR-P, transurethral resection of the prostate; CRPC, 
castration-resistant prostate cancer; BR, biochemical recurrence; PSA, prostate-specific antigen; TDSF, tumor-derived soluble 
factors; IDO, indoleamine 2, 3-dioxygenase; TNFR1, tumor necrosis factor receptor 1; IFNGR1, 2, interferon gamma receptor 
1, 2; RFS, recurrence-free survival; AUC, area under the curve; ROC, receiver operating characteristic.
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addition, prostate adenocarcinoma outgrowth is frequently 
detected in tissue areas adjacent to chronic inflammation 
(3, 4). However, other studies suggest that histologically 
detectable prostate inflammation associates with decreased 
PCa risk (7, 8).
Previous studies by us and others indicate that genes encoding 
pro-inflammatory cytokines are expressed to significantly higher 
extents in PCa than in benign prostatic hyperplasia (BPH) tissue 
specimens (9–11).
Chronic inflammation frequently results in the establishment 
of an immunosuppressive microenvironment, particularly in cancer 
tissues (12, 13). In this context, pro-inflammatory cytokines might 
promote survival and proliferation of tumor cells and, paradoxi-
cally, subvert adaptive immune responses (13). Numerous studies 
indicate that chronic immune-stimulation may result in immune 
tolerance. Overstimulated T  cells do express “immunological 
checkpoint” receptors whose triggering by specific ligands results 
in their anergy. Notably, the expression of some ligands of these 
receptors is typically induced by IFN-γ. These concepts provide 
the basis for the use of specific biologicals in cancer treatment 
and represent an important link between the potential immuno-
genicity of tumor microenvironment and the neutralization of 
immune responses (14).
IFN-γ and TNF-α are typically produced in the context of 
ongoing immune responses against infectious and tumor chal-
lenges. However, TNF-α has also been proposed as PCa marker 
(15). TNF-α might exert pro- or antiapoptotic effects, depending 
on cell or tissue types and experimental conditions (16, 17). High 
levels of TNF-α lead to tumor cell necrosis and apoptosis (18), 
and mediate immune cytotoxicity and production of inflam-
matory cytokines (19). In contrast, low-dose paracrine TNF-α 
production in tumor areas may support chronic inflammation 
and cancer progression (20).
Regarding IFN-γ, PCa cells have been shown to be poorly 
sensitive to its cytotoxic effects (21). Furthermore, it has been 
suggested that IFN-γ might induce immune-suppressive effects 
in PCa (22, 23).
In this study, we have comparatively analyzed the expression 
of genes encoding IFN-γ, TNF-α, and their receptors in PCa 
and in BPH tissues. Moreover, we have investigated the ability of 
these cytokines to induce in PCa cells the production of factors 
promoting tumor progression through the inhibition of adaptive 
immune responses (24) and/or the activation of alternative path-
ways for the androgen receptor (25). Finally, we have addressed 
the prognostic significance of factors induced by IFN-γ and TNF-
α in PCa cells and their potential predictive power when detected 
in urine of individuals at risk of developing this malignancy.
MaTerials anD MeThODs
Patients
We studied two case series of 97 consecutive PCa patients 
undergoing radical prostatectomy and 35 consecutive BPH 
patients undergoing conventional transurethral resection of the 
prostate (TUR-P) enrolled in the Department of Urology of 
the University Hospital of Basel, Switzerland, from 2007 to 2011. 
Clinicopathological parameters [prostate-specific antigen (PSA) 
levels, tumor stage, and Gleason score] were assigned according 
to EAU guidelines for PCa (uroweb.org/guideline/prostate-
cancer/). If a PCa patient had a tumor whose stage at diagnosis 
could not be assessed, the Gleason score at biopsy was reported. 
BPH urinary obstructive symptoms and acute urinary retention 
were evaluated according to the international prostate symptom 
score. Biochemical recurrence (BR) was documented in 21 of 97 
patients (21.6%) over a median follow-up of 23 months (range, 
3–63  months). Local ethics committee approval and written 
informed consent from patients were obtained in accordance 
with the requirements of the Ethical Committee of Basel-Stadt 
and Basel-Land (EKBB, Ref. Nr. EK: 176/07). For the detection 
of indoleamine 2,3-dioxygenase (IDO) and interleukin (IL)-6 
gene expression in urines of individuals at risk of developing 
PCa, we collected urines of 27 consecutive patients before they 
underwent fine needle biopsy for diagnostic/prognostic purposes 
(KEK-ZH-NR: 2010-0081/0).
cell culture
Established human PCa cell lines CA-HPV-10 [immortalized cell 
line from high-grade adenocarcinoma; American Type Culture 
Collection (ATCC)®CRL-2220] and PC3 (lumbar metastasis; 
ATCC®CRL-1435) were purchased from the ATCC (LGS 
Standards). Cells were cultured according to Russel and Kingsley 
guidelines (26). In particular, keratinocyte serum-free medium, 
supplemented with 50  µg/ml bovine pituitary extract, and 
Roswell Park Memorial Institute 1640 medium, supplemented 
with 10% fetal bovine serum, were used. All experiments were 
performed with cells at passage 9 or below. Cells were regularly 
tested for mycoplasma contamination by PCR (LookOut® myco-
plasma qPCR detection kit, Sigma-Aldrich, Switzerland), prior 
to experimental procedures. Cells were cultured in T75 flasks 
and, when reaching 80% confluence, were stimulated with either 
IFN-γ or TNF-α, at a concentration of 300 U/ml (eBioscience, 
San Diego, CA, USA) or left unstimulated. Cells were harvested at 
different time points (6, 12, and 24 h for PC3 and 6, 12, 24, 48, and 
72 h for CA-HPV-10). For inhibition tests, cells stimulated with 
IFN-γ or TNF-α (300 U/ml) or left unstimulated were cultured 
for 24 h in the presence of ruxolitinib (INCB018424; 1 µM) (27), 
SB202190 (20 µM) (28), LY294002 (50 µM) (29) (Selleckchem.
com, Houston, TX, USA), or PDTC (10 µM; Sigma-Aldrich) (30) 
or without inhibitors. Cells were then collected by trypsinization 
(trypsin-EDTA, Invitrogen, Carlsbad, CA, USA) and used for 
gene expression analysis.
gene expression analysis
Whole-mount prostatectomy sections of patients’ tissue speci-
mens were analyzed for the presence of tumors by experienced 
pathologists. Total RNA was extracted from tumor tissues by 
the RNeasy® MiniKit (Qiagen, Basel, Switzerland), treated with 
deoxyribonuclease I (Invitrogen), and reverse transcribed by using 
M-MLV Reverse Transcriptase (Invitrogen). Quantitative gene 
amplification (qRT-PCR) was performed by using an ABI Prism 
7500 FAST sequence detection system with the TaqMan® Universal 
PCR Master Mix and primers and probes provided by Assays-on-
Demand, Gene Expression Products (Life Technologies, Forster 
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City, CA, USA). Normalization of gene expression was performed 
by using GAPDH gene as reference. The 2−ΔΔCt method was used 
to compute the fold change in the expression of genes of interest 
when compared with GAPDH gene expression as baseline. Values 
≤10−7 were considered undetectable. For cell line analysis, cells 
were cultured, stimulated, and harvested as described above, and 
gene expression was similarly evaluated.
Measurement of Tryptophan and 
Kynurenine concentrations
Measurement of tryptophan and kynurenine concentrations in 
supernatants of cytokine-treated and -untreated cell lines, col-
lected at defined time points was performed by high-pressure 
liquid chromatography (HPLC) and fluorimetric detection, as 
previously described (31). Supernatants were deproteinized by 
mixing with an equal volume of 10% (w/v) trichloroacetic acid. 
Measurement of tryptophan by HPLC separation was performed 
with a reverse-phase column (Spherisorb S5 ODS2, 25 cm) and a 
mobile phase (1 ml/min flow rate) composed of 5% acetonitrile, 
100 mM phosphate buffer, pH 3.6, and 1 mM EDTA. Detection 
was performed with a Perkin-Elmer (Foster City, CA, USA) model 
LC 240 fluorimeter. The excitation and emission wavelengths 
were 313 and 420 nm, respectively. Kynurenine was measured by 
HPLC and UV detection. Briefly, HPLC separation was obtained 
with a reverse-phase column (Spherisorb S5 ODS2, 10 cm) and a 
mobile phase (1 ml/min flow rate) composed of 2% acetonitrile, 
0.1 mM ammonium acetate, and 100 mM acetic acid. Kynurenine 
was detected at 365  nm with a UV detector (Perkin-Elmer 
model LC 90).
elisa assays
Supernatants of cytokine-treated and -untreated cell lines were 
collected at defined time points, centrifuged for 10  min at 
1,280 rpm to discard the cell debris, and subsequently stored 
at −80°C. IL-6 release was quantified by using a commercially 
available ELISA kit (eBioscience) according to the manufacturer’s 
instructions.
Flow cytometry analysis
To evaluate expression of IFN-γ and TNF-α receptors, cells were 
stained with fluorescein isothiocyanate (FITC)-conjugated anti-
interferon gamma receptor 1 (IFNGR1) mAb, allophycocyanin 
(APC)-conjugated anti-IFNGR2 mAb (R&D, Minneapolis, MN, 
USA), FITC-conjugated anti-tumor necrosis factor receptor 1 
(TNFR1) mAb (Abcam), and phycoerythrin (PE)-conjugated 
anti-TNFR2 mAb (BD Pharmingen, San Diego, CA, USA). Data 
were acquired on a FACSCalibur® cytometer (Becton Dickinson, 
Franklin Lakes, NJ, USA) and analyzed by FlowJo software.
immunohistochemistry
Representative 5-μm-thick sections of prostatic adenocarcinoma 
were cut from formalin-fixed and paraffin-embedded specimens 
and evaluated by immunohistochemistry with primary mono-
clonal antibodies anti-TNF-α (clone 52B83) and anti-IFN-γ  
(clone LLOSZ), using a Ventana Benchmark instrument (Ventana, 
Vreden, Germany). As positive controls, sections from reactive 
lymph nodes were used.
scratch Wound healing assay
Cytokine-treated and -untreated cell lines were seeded in trip-
licates in six-well plates and grown until confluent. Identical 
scratches were generated both vertically and horizontally with 
a 200-µl sterile pipette tip, creating a cross-shaped empty area. 
Cellular debris were removed by washing with PBS. Cells were 
center-imaged at 5× magnification, using a Zeiss Axiovert 200 M 
microscope equipped with a Zeiss AxioCam MRm camera with 
maximum contrast (Carl Zeiss AG, Feldbach, Switzerland; soft-
ware: Axio Vision Rel. 4.7). For cell stimulation, either IFN-γ or 
TNF-α were added to the wells at a final concentration of 300 U/ml. 
The closure rate of the empty area was analyzed after 12 and 
24 h. Data were evaluated with T-scratch software with default 
parameter setting.
Boyden chamber invasion assay
Cell invasion assays were performed in a Boyden chamber system 
using the Chemicon Cell Invasion Assay Kit (Millipore, Billerica, 
MA, USA), according to the manufacturer’s protocol. Cells were 
seeded in a 24-well plates (200,000 cells/well) in serum-free con-
ditions in an ECMatrix-coated insert and stimulated with either 
cytokine afterward. Complete medium (10% FCS) was used as 
a chemoattractant and was placed in the bottom chamber of 
the plate. Cells were allowed to migrate for 48 h. Invading cells 
were then collected and quantified using the CyQuant GR dye 
(Millipore). All experiments were conducted in duplicate and 
repeated three times. Results are expressed as percentages of 
invading cells compared with unstimulated controls.
Urine Processing
For urine tests, 20 ml of urine collected before biopsy were cen-
trifuged at 2,000 rpm for 10 min. Total RNA was extracted from 
cell pellet by adding 700 µl of lysis solution to the pellet (RNA 
Aqueous isolation kit, Ambion). The elution step was performed 
by adding twice 50 µl of DNAse/RNAse free water (final volume 
100 µl). For reverse transcription, 30 µl of RNA were added to 
30 µl of a mix prepared with the High Capacity cDNA Reverse 
Transcription Kits (Applied Biosystems). The IDO assay (Custom 
TaqMan primers and probe design; Applied Biosystems) was 
designed to cover the exon–exon junction between exon 9 and 10. 
Primers were designed to allow a melting temperature between 
58 and 61°C, with an optimal length of 20 bp and CG content 
between 30 and 80%. The probe was designed not to start with 
G and in order to have a melting temperature 10°C higher than 
the one of the primers. A 3′ minor grove binder-probe [non-
fluorescent quencher fitting the 5′ 6-carboxy fluorescein (FAM) 
spectral qualities] was used. Primers and probe were used at a 
final concentration of 400 and 200 nM, respectively. TaqMan assay 
sequences are described in patent PCT/EP2017/076169. Gene 
quantification was performed by qRT-PCR as described above.
statistical analysis
Statistical analyses were performed with GraphPad Prism (v5.1) 
and SPSS (v23). For the analysis of cell line data, the Mann–
Whitney U test was used to compare the mean expression of 
specific genes or protein release for independent samples. For the 
analysis of patient data, non-parametric tests for gene expression 
TaBle 1 | Distribution of tumor-derived soluble factors (TDSFs) gene expression 
in prostate cancer (PCa) and benign prostatic hyperplasia (BPH) tissues.
TDsFs Pca; n = 64 BPh; n = 35 p-Valuea
IFNγ 50 (78%) 22 (63%) 0.1
TNFα 62 (97%) 31 (90%) 0.1
IDO 58 (91%) 18 (51%) <0.0001
IL-6 47 (73%) 18 (51%) 0.03
aTwo-sided Pearson χ2 test.
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levels (Mann–Whitney U test), correlation of gene expression 
between two factors (Spearman’s ρ), and frequency of expression 
between two groups of patients (Pearson χ2) were evaluated. For 
contingency table analysis, Fisher’s exact test was performed. 
For survival analysis, estimates of recurrence-free survival (RFS) 
were calculated by the Kaplan–Meier method and compared by 
the log rank test. Endpoint was time from surgery to BR, with 
censoring of data from patients who were BR negative at the time 
of their last follow-up visit. A univariate Cox regression analysis 
was performed to evaluate the hazard ratio (HR) for recurrence 
in IDO- and IL-6-positive patients. A multivariate Cox regres-
sion analysis was used to determine the independent prognostic 
relevance of both factors for the analyzable patients. For all tests, 
differences with P ≤ 0.05 were considered significant.
resUlTs
iFn-γ and TnF-α gene expression in Pca 
Tissues
IFN-γ and TNF-α play key roles in acute and chronic inflamma-
tion. To obtain an insight into their potential relevance in PCa, 
we analyzed the expression of genes encoding these cytokines in 
tissue specimens from 64 patients collected after radical prosta-
tectomy (RP) for primary PCa. Tissue specimens from patients 
treated for BPH (n = 35) were tested as controls.
Ex vivo analysis showed that IFN-γ and TNF-α genes are 
expressed with similar frequency in PCa and BPH. In particular, 
IFN-γ gene was expressed in 78 and 63% of cases, respectively 
(p = 0.1), whereas TNF-α gene expression was detected in 97% of 
PCa tissues and 90% of BPH tissues (p = 0.1) (Table 1). However, 
expression levels of both genes were significantly higher in BPH 
than in PCa specimens (IFN-γ, p <  0.01; TNF-α, p <  0.0001) 
(Figure 1A).
Remarkably, gene expression levels of these two pro- 
inflammatory cytokines were significantly correlated with each 
other in PCa (n = 49; r = 0.42; p < 0.01) (Figure 1B), but not in 
BPH tissues (n = 35, r = 0.2; p = 0.2, data not shown).
At the protein level, cancer cells showed only slight and focal 
cytoplasmic IFN-γ specific immunostaining and slight diffuse 
positivity along cell membranes to anti-TNF-α antibody. In 
contrast, interstitial inflammatory cells were intensely positive 
for both antibodies (Figures 1C,D).
Thus, consistent with putatively ongoing inflammation states, 
expression of both IFN-γ and TNF-α is detectable at the gene and 
protein level in both PCa and BPH tissues.
Pca cells express iFn-γ and TnF-α 
receptors
IFN-γ and TNF-α expression in tissues urged us to explore the 
direct effects of these cytokines on PCa cells. As “in vitro” model, 
we chose two established cell lines originating from localized, 
CA-HPV-10, and metastatic, PC3, cancers. In preliminary experi-
ments, we evaluated the expression of IFN-γ and TNF-α receptors 
in these cells. CA-HPV-10 and PC3 cells expressed IFNGR1 
cytokine binding chain and, to higher extents, IFNGR2 accessory 
chain, at both gene (Figure 2A) and protein levels (Figures 2B,C). 
Furthermore, expression of the gene encoding TNFR1, the main 
receptor for soluble TNF-α (32), was detectable in both PCa cell 
lines (Figure 2D). However, TNFR1 protein expression was mod-
est, and almost negligible in both cell lines, as assessed by Western 
blot and flow cytometry tests (data not shown).
Pro-inflammatory stimuli enhance the 
expression of Tumor-Derived soluble 
Factors involved in Pca Progression
IFN-γ and TNF-α receptor expression by PCa cells suggested that 
these cytokines could directly stimulate tumor cells. To address 
this issue, we analyzed the ability of IFN-γ and TNF-α to modu-
late the expression of a panel of genes encoding a variety of factors 
known to be produced by tumor cells and of potential relevance 
in tumor progression and inhibition of immune responses (33). 
These genes were expressed to different extents in the PCa cells 
under investigation. In particular, IDO, IL10, and HGF genes 
were constitutively expressed in PC3, but not in CA-HPV-10 cells 
whereas expression levels of IL6, ANG1, eNOS, and PDGF-BB 
genes were 2.5-fold higher in PC3 than in CA-HPV-10 cells. On 
the other hand, IL1β and MMP-9 were detected at higher levels in 
CA-HPV-10 than in PC3 (>2.5-fold). Additional genes, includ-
ing TGFβ1, VEGF-A, -C, and -D, CCR7, MMP-2, ARG II, i-NOS, 
ANG2, and FRAG1, were similarly expressed in both cell lines. It 
is noteworthy that TNF-α gene was constitutively expressed in 
both cell lines, whereas IFN-γ was undetectable (Table 2).
Differential effects of iFn-γ and TnF-α 
stimulation of established Pca cell lines
IFN-γ and TNF-α failed to modulate the expression of the large 
majority of the genes under investigation (Table  2). However, 
IFN-γ stimulation significantly enhanced IDO gene expression 
(>400-fold after 6  h) in PC3 cells (Figure  3A, black lines). In 
addition, IFN-γ induced upon 6 h stimulation the de novo expres-
sion of IDO gene in CA-HPV-10 cells at levels 10-fold higher than 
those constitutively observed in PC3 cells (Figure 3A, red lines). 
TNF-α stimulation also significantly enhanced IDO expression 
in PC3 cells 3.6-fold above constitutive levels, although to a 
lesser extent, when compared with IFN-γ induction (p =  0.03; 
Figure 3B). However, TNF-α failed to induce de novo IDO gene 
expression in CA-HPV-10 cells.
To validate these findings, we evaluated IDO functional activity 
by testing tryptophan/kynurenine ratios in culture supernatants. 
In agreement with gene expression results, consistent with incr-
eased IDO functional activity, a marked decrease in tryptophan/
kynurenine ratio was observed in supernatants from IFN-γ and 
FigUre 1 | Expression of IFN-γ and TNF-α genes and immunohistochemical cytokine detection in prostate cancer (PCa) tissues. (a) Expression of IFN-γ and  
TNF-α genes in PCa (black triangles) and benign prostatic hyperplasia (BPH) (open triangles). A higher expression of both cytokine genes in BPH than in PCa tissue 
specimens was observed (Mann–Whitney U test, IFN-γ p < 0.01 and TNF-α p < 0.0001). The 2−ΔΔCt method was used to compute fold changes in gene expression 
for both cytokines, setting GAPDH gene expression equal to 1. Values ≤107 were considered undetectable. (B) Fold changes in IFN-γ gene expression in either  
BPH or PCa tissue specimens were plotted against fold changes in TNF-α gene expression in same specimens. A significant correlation was only observed in PCa 
(Spearman rank correlation coefficient, r = 0.42; p < 0.01). (c,D) A representative image by immunohistochemistry (original magnification 200×; slight hematoxylin 
conterstaining) of a poorly differentiated prostatic adenocarcinoma (Gleason score 9) tissue specimen stained with (c) IFN-γ or (D) TNF-α.
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TNF-α treated PC3 cells and from IFN-γ stimulated CA-HPV-10 
cells. Notably, in PC3 cells, IDO activity was increased upon 6 h 
IFN-γ induction whereas upon TNF-α stimulation, it was signifi-
cantly detectable only after 12 h. In keeping with qRT-PCR data 
indicating de novo IDO gene expression upon IFN-γ stimulation, 
increased IDO-related enzymatic activity in CA-HPV-10 cells 
was detectable with delayed kinetics after 24–72 h (Figure 3C). As 
expected, TNF-α treatment of CA-HPV-10 cells was ineffective 
(negligible expression in Table 2).
On the other hand, TNF-α, but not by IFN-γ, induced overex-
pression of IL-6 gene in both PC3 and CA-HPV-10 cells (Table 2) 
and, in accord with gene expression data, IL-6 release in super-
natants of IFN-γ and TNF-α stimulated cells was significantly 
enhanced in both cell lines by TNF-α treatment (Figure  3D). 
Given the direct involvement of IL-6 in PCa progression (25), we 
performed two functional assays to investigate the effect of TNF-
α and IFN-γ on the ability of PCa cells to migrate and invade. In 
our experimental conditions, CA-HPV-10 showed very limited 
migratory capability, which was unaffected by either cytokine, 
whereas PC3 showed a constitutively high motility, which was 
significantly enhanced by TNF-α (12 h, p < 0.01; 24 h, p < 0.001) 
(Figures  3E,F). In addition, we observed that TNF-α strongly 
increased the invasiveness of PC3 by 53% (p =  0.03) and the 
invasiveness of CA-HPV-10 to a lesser extent by 32% (p = 0.04), 
when compared with IFN-γ-treated (PC3 24% and CA-HPV-10 
8%) or -untreated cells (Figure 3G). Taken together these data 
indicate that inflammatory cytokines potentially present in PCa 
microenvironment are able to upregulate the expression of a 
restricted number of genes encoding factors of interest in PCa 
immunobiology.
iFn-γ and TnF-α activate JaK1/2 and 
p38MaPK Pathways in Pca, respectively
To confirm the ability of IFN-γ and TNF-α to stimulate PCa 
cells, we investigated the ability of well-characterized inhibitors 
of their signal transduction pathways to prevent their effects. 
Inhibition of the JAK1/2 pathway by ruxolitinib dramatically 
reduced IDO gene expression induced by IFN-γ in both PC3 
(p = 0.02) and CA-HPV10 (p = 0.04) cells (Figure 4A). In con-
trast, NF-kB, p38MAPK, and PI3K inhibitors were ineffective 
(data not shown). Instead, inhibition of the p38MAPK pathway 
FigUre 2 | Interferon gamma receptors (IFNGRs) and tumor necrosis factor receptor 1 (TNFR1) gene and protein expression in prostate cancer (PCa) cell lines.  
(a) Gene expression of IFNGR1 (white bars) and IFNGR2 (gray bars) in PC3 and CA-HPV-10 cell lines. A higher expression of IFNGR2 than of IFNGR1 was 
observed in both cell lines (Mann–Whitney U test, PC3 p = 0.05 and CA-HPV-10 p = 0.02). (B) Mean fluorescence intensity (MFI) by fluorescent-activated cell 
sorting of IFNGR1 (white boxes) and IFNGR2 (gray boxes) specific staining in PC3 and CA-HPV-10 cell lines. (c) Representative overlaid histograms refer to MFI  
of IFNGR1 and IFNGR2, when compared with isotype staining. IFNGR2 was expressed to higher extents than IFNGR1 only in PC3 (Mann–Whitney U test, p = 0.03). 
IFNGR1 was expressed to a higher level in CA-HPV-10 than in PC3 cells (Mann–Whitney U test, p = 0.03). (D) TNFR1 gene expression in PC3 and CA-HPV-10 cell 
lines. No significant differences were observed between cell lines (Mann–Whitney U test).
6
Banzola et al. IFN-γ- and TNF-α-Driven PCa Progression
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 1051
by SB202190 markedly reduced TNF-α-induced expression of 
IL-6 (p < 0.01), and IDO (p = 0.01) genes in PC3 cells and of IL-6 
(p = 0.02) gene in CA-HPV10 cells (Figure 4B). However, inhibi-
tion of the NF-kB and PI3K pathways with PDTC and LY294992, 
respectively, did not significantly affect TNF-α stimulation in 
either cell lines (data not shown), suggesting a hierarchy of signal 
transduction checkpoints.
gene expression Profiling in clinical 
specimens
“In vitro” data indicated that IFN-γ and TNF-α were able to 
enhance expression of IDO and IL-6 at the gene and protein 
level in PCa cells. Based on this background, we explored the 
expression of genes encoding these factors and their correlations 
in surgical BPH and PCa specimens.
Consistent with previous reports from our group (9), we 
observed that the frequency of detection of IDO (91% in PCa vs. 
51% in BPH, p < 0.0001) and IL-6 (73% in PCa vs. 51% in BPH, 
p = 0.03) gene expression were significantly higher in PCa than 
in BPH tissues (Table 1). Similarly, their expression levels (IDO: 
p < 0.001 and IL-6: p < 0.0001) were significantly higher in PCa 
than in BPH tissues (Figures 5A,B).
Most interestingly, in PCa patients, IDO gene expression levels 
appeared to highly significantly correlate with those of IFN-γ 
(n = 48, r = 0.54; p < 0.001), and, to a lower extent, of TNF-α 
gene (n = 58, r = 0.37; p < 0.01) (Figure 5C). Intriguingly, but 
consistent with our “in  vitro” data, levels of IL-6 gene expres-
sion correlated more significantly with those of TNF-α (n = 46, 
r = 0.56; p < 0.0001) than with those of IFN-γ (n = 39, r = 0.41; 
p < 0.01) gene expression (Figure 5D).
Prompted by these data, we also analyzed the expression of 
genes encoding IFN-γ and TNF-α receptors in clinical specimens. 
In our cohort of PCa patients, IFNGR2 gene expression was simi-
lar in PCa and BPH tissues. In contrast, expression of IFNGR1 
gene, encoding the cytokine binding chain of the receptor, was 
significantly higher in PCa than in BPH tissues (p <  0.0001) 
(Figure 5E). Notably, TNFR1 gene also appeared to be expressed 
TaBle 2 | Constitutive and cytokine-stimulated expression of genes encoding 
tumor-derived soluble factors involved in prostate cancer (PCa) progression (33).
constitutive 
expression over 
24 h
enhanced  
expression upon
iFnγ TnFα
ca-hPV-10 Pc3 ca-hPV-10 Pc3 ca-hPV-10 Pc3
TGFβ1 TGFβ1
IL1β IL1β
IL-6 IL-6A
IL10 IL10
VEGF-A VEGF-A
VEGF-C VEGF-C
VEGF-D VEGF-D
CCR7 CCR7
MMP2 MMP2
MMP9 MMP9
IDO IDO
ARG II ARG II
eNOS eNOS
iNOS iNOS
ANG 1 ANG1
ANG 2 ANG2
FRAG1 FRAG1
HGF HGF
PDGF-BB PDGF-BB
TNFα TNFα
IFNγ IFNγ
 Constitutive gene expression, as compared with β-actin gene expression as 1, 
range 1.5- to 2.5-fold. Expression <1.5-fold no-reproducible gene.
 Significant relative gene expression (ΔΔCt ≥ 2.5-fold).
 Negligible expression (≤10−7).
 No relevant fold increase upon TNF-α or IFN-γ stimulation.
 Gene expression at 6 hours over the constitutive expression (ΔΔCt ≥ 2.5-fold).
 Gene expression at 12 hours over the constitutive expression (ΔΔCt ≥ 2.5-fold).
 Negligible expression (≤10−7).
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(95% CI, 49–60%; SE  =  2.8; p  <  0.001) for IDOlowpatients 
(Figure  6B). Overall, BR  +  patients showed a significantly 
higher expression of IDO gene than BR− patients (p <  0.001, 
Figure  6C). Cox regression analysis indicated that IDOhigh PCa 
patients had a higher risk of BR than did IDOlow PCa patients 
(HR 3.1, p < 0.01, Table 3). In multivariate analysis, IDOhigh PCa 
patients maintained a significant higher risk of BR than IDOlow 
PCa patients, irrespective of established predictors (Table 4).
For IL-6, 95% CI of AUC persistently included the 0.50 limit, 
consistent with a lack of prognostic potential. Indeed, neither a 
significant association between IL-6 gene expression levels and 
BR nor a significant impact on RFS were detectable (Figure S1 in 
Supplementary Material).
Contingency table analysis did not provide any evidence for 
an association between IDO gene expression in tumor specimens 
and three classical clinicopathological parameters, PSA, pT, and 
Gleason score, while IL-6 gene expression was associated with 
PSA (p =  0.02) and showed a trend toward association with 
Gleason score (p = 0.06) (Table 5).
iDO as Diagnostic and Prognostic Tool 
When Detected at gene level in Urine  
of Men at risk of Developing Pca
Capitalizing on data from surgical specimens, we hypothesized 
that IDO might represent a novel biomarker for PCa in urine. 
We studied 27 patients undergoing first time prostate biopsy for 
being at risk of PCa (based on positive digital rectal examina-
tion (DRE) and PSA serum level >4 ng/ml). Nineteen out of 27 
prostate biopsies were positive for PCa (localized PC), while 4 
were BPH and 4 were negative (normal tissue). Our data show 
that the quantification of IDO mRNA in urine of patients 
before undergoing biopsy for diagnostic procedures has a very 
promising ability to identify those harboring PCa. The AUC to 
dichotomize individuals based on the presence or absence of 
cancer defined a cutoff level of 0.0015 (Figure  7A). Therefore, 
with IDO ≤ 0.0015 gene expression levels, PCa risk is negligible 
(NPV 100%, PPV 82%). The AUC to dichotomize patients with 
indolent or aggressive PCa based on GS defined a cutoff level of 
0.0096 (Figure 7B). It says that 87.5% of patients with indolent 
PCa (GS ≤ 6 and BR− and no treatment after biopsy), 100% of 
patients with no PCa, and 27% of patients with clinically relevant 
PCa (GS ≥ 7, BR−, treatment after biopsy) expressed IDO below 
0.0096 (73% of patients with clinically relevant PCa above 0.0096; 
NPV 83%, PPV 88%) (Figure 7C). Overall, the IDO test might 
reduce the number of unnecessary biopsies by 14.8% with cutoff 
0.0015 and 66.6% with cutoff 0.0096. Detection of IL-6 in urines 
of same individuals was neither effective in predicting patients 
bearing PCa nor in identifying, among diagnosed PCa, those at 
risk of developing an aggressive tumor (data not shown).
DiscUssiOn
Pre-existing chronic inflammation has repeatedly been reported 
to play a key role in PCa outgrowth and progression (4). However, 
underlying molecular mechanisms are largely unclear. In this 
study, we have utilized clinical specimens and established cell 
to significantly higher extents in PCa than in BPH specimens 
(p < 0.01) (Figure 5F).
iDOhigh Patients are at higher risk of 
Developing Br in Pca
Our “in vitro” results indicated that IFN-γ and TNF-α were able 
to enhance the expression of IDO and IL-6 at gene and protein 
level in PCa cells. Furthermore, “ex vivo” data documented that 
both IDO and IL-6 genes are expressed to higher extents in PCa 
than in BPH, and that their expression is highly significantly cor-
related with that of IFN-γ and TNF-α genes. Taken together these 
results urged us to address the prognostic significance of IDO and 
IL-6 gene expression in 97 PCa, following RP.
We focused our analysis on the timing of so-called BR, as 
defined by PSA values ≥0.1  ng/ml. The prognostic relevance 
of the genes under investigation was evaluated using receiver 
operating characteristic (ROC) curve analysis. For IDO, the 
calculated area under the curve (AUC) for RFS was 0.78 
(95% CI, 0.67–0.88%) (Figure  6A). ROC analysis for RFS 
defined an optimal cutoff level of 9.83 ×  10−4 to dichotomize 
the patients into IDOhigh and IDOlow groups (specificity 78%, 
sensitivity 67%). Estimated rate of 5-year RFS was 32% 
(95% CI, 26–38%, SE  =  3.02) for IDOhigh patients and 55% 
FigUre 3 | Continued
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lines to obtain innovative insights into the relationship occur-
ring between expression of IFN-γ and TNF-α pro-inflammatory 
cytokines in PCa tissues, and tumor progression.
Our data indicate that expression of genes encoding IFN-γ 
and TNF-α is detectable in both BPH and PCa specimens. 
Intriguingly, the expression of both genes is significantly higher 
in BPH than in PCa tissues (34). However, expression of specific 
receptors appears to be higher in PCa than in BPH. Thus, these 
cytokines, produced by a variety of interstitial inflammatory cells, 
might be highly effective within malignant tissues. Remarkably, 
expression of IFN-γ and TNF-α genes is significantly correlated 
only in PCa, suggesting common induction mechanisms.
We used an in vitro model based on cell lines originating from 
localized, CA-HPV-10, and metastatic, PC3, disease to address 
direct effects of IFN-γ and TNF-α on PCa cells. Among a group 
of genes responsible for cell contact independent mechanism of 
FigUre 4 | Interferon gamma receptor 1, 2 and tumor necrosis factor receptor 
1 involvement in IFN-γ- and TNF-α-dependent indoleamine 2,3-dioxygenase 
(IDO) and interleukin (IL)-6 production. (a) IDO gene expression upon IFN-γ 
stimulation was significantly reduced by inhibition of the JAK-STAT signaling 
pathway with ruxolitinib in both cell lines tested (about 4-log less in PC3 and 
5-log less in CA-HPV-10 cell lines). (B) The expression of IL-6 and IDO genes 
upon TNF-α stimulation was significantly reduced by inhibition of the p38MAPK 
kinase signaling pathway with SB202190 in both cell lines (Mann–Whitney U 
test). Experiments were conducted in triplicate and data are shown as box and 
whisker plot with SDs.
FigUre 3 | Gene expression of indoleamine 2,3-dioxygenase (IDO) and interleukin (IL)-6 and their functional activity in cell lines. (a) IDO gene expression upon IFN-γ 
induction of either PC3 (black lines and circles) or CA-HPV-10 (red lines and squares) cell lines was calculated as twofold higher than its constitutive expression in PC3. 
The cytokine induced a significantly higher IDO fold increase in PC3 than in CA-HPV-10 cell lines at 6, 12, and 24 h (Mann–Whitney U test). (B) IDO gene expression 
upon TNF-α stimulation was 2-fold less than upon IFN-γ. (c) IDO activity was measured as the tryptophan/kynurenine ratio detected in the cell supernatants. IFN-γ 
(black squares) induced a stronger enzymatic activity of IDO than did TNF-α (black triangles) in PC3, while to a lesser extent in CA-HPV-10 (red triangles). The test was 
carried out with pooled supernatants from three different experiments for each cell line under investigation cultured in the indicated conditions. Due to the negligible 
expression of IDO at constitutive level in CA-HPV-10 (Table 2 for gene expression at constitutive level), we did not measure tryptophan/kynurenine ratio in the 
supernatant of unstimulated CA-HPV-10 (control). (D) Protein release (pg/ml) of IL-6 in supernatant of CA-HPV-10 (above) or PC3 (below) cell lines treated with IFN-γ 
(light gray bars) or TNF-α (dark gray bars), when compared with untreated cell lines (white bars). Overall, TNF-α induced the highest release of the cytokine, compared 
with IFN-γ induction, in both cell lines at all-time points tested (Mann–Whitney U test). (e) Cell migration was assessed by a scratch wound healing assay, as shown in 
one representative experiment out of three by confocal microscopy. In our experimental conditions, CA-HPV-10 showed very limited migratory capability, which was 
unaffected by either cytokine, while PC3 showed a constitutively high motility, which was significantly enhanced by TNF-α (12 h, p < 0.01; 24 h, p < 0.001). (F) Boxes 
and whiskers representing migration potential of PC3 cells based on the quantification in percentage of empty area when compared with time 0 (100% empty area) 
upon treatment with IFN-γ (light gray boxes) or TNF-α (dark gray boxes) at time points of 12 h (p < 0.01) and 24 h (p < 0.0001; two-way ANOVA test) when compared 
with control. Data are expressed as averages of triplicates for each condition. (g) For the Boyden chamber cell invasion analysis, cells were allowed to invade the 
membrane matrix for 48 h. The invading cells were then collected and quantified using the CyQuant GR dye to measure the invasiveness of both CA-HPV-10 and PC3 
after treatment with IFN-γ (black bars) or TNF-α (gray bars). We observed that TNF-α strongly increased the invasiveness of both CA-HPV-10 (54.08 ± 0.12%, 
p = 0.04) and PC3 (59.67 ± 0.21%, p = 0.03), when compared with IFN-γ-treated cells (CA-HPV-10, 8.08 ± 0.29%; PC3, 21.96 ± 0.19%). The results were calculated 
as percentages of invading cells compared with unstimulated controls. All experiments were conducted in duplicate and repeated three times.
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tumor promotion and reportedly impacting on cancer progression 
(33), IDO and IL-6 genes were the only ones consistently over-
expressed in PCa cells upon stimulation with IFN-γ or TNF-α. In 
particular, IFN-γ induced IDO gene upregulation in both cell lines 
under investigation, whereas TNF-α induced IL-6 gene overexpres-
sion in both cell lines and IDO gene overexpression in PC3 cells.
These findings, supported by ELISA and functional data have 
prompted us to investigate their clinical significance. Ex vivo 
results indicate that expression of IDO and IL-6 genes in PCa 
tissues is significantly correlated with IFN-γ and TNF-α gene 
expression. Most importantly, we observed that IDO, but not 
IL-6, gene expression predicts BR.
Taken together our data confirm and extend previous reports 
from our group (9). More interestingly, they unravel novel molecu-
lar mechanisms underlying the association between inflammation 
and PCa progression and suggest that cancer cell-specific molecu-
lar alterations (35) and concomitant inflammation (13), might 
independently contribute to give rise to highly aggressive PCa.
Indoleamine 2,3-dioxygenase is a tryptophan-depleting enz yme 
that has been thoroughly investigated by immunologists because 
of its involvement in the mechanisms of immune regulation (24). 
IDO blunts T  lymphocyte expansion (36), thereby powerfully 
inhibiting adaptive immune responses. On the same line, more 
recently, IDO has been shown to induce resistance to treatment 
with therapeutic monoclonal antibodies targeting immunological 
checkpoints (37). These effects have been shown to be mediated, 
at least in part, by regulatory T cells-dependent recruitment and 
activation of myeloid-derived suppressor cells (38).
Most interestingly, in murine cancer models, high-IDO activ-
ity, resulting in accelerated tumor progression, is associated to 
immune responses and to high expression in the tumor microen-
vironment of pro-inflammatory cytokines, including IFN-γ and 
TNF-α (37). Notably, IFN-γ and TNF-α have previously been 
shown to powerfully synergize in the induction of IDO, although 
to different extents (39–42).
Exogenous administration of TNF-α also induced IL-6 release 
in both cell lines under investigation. IL-6 gene expression was 
also detected at significantly higher levels in PCa than in BPH 
specimens and was highly significantly correlated with TNF-α 
FigUre 5 | Gene expression profiling in clinical specimens. Gene expression of (a) Indoleamine 2,3-dioxygenase (IDO) and (B) interleukin (IL)-6 genes in prostate 
cancer (PCa) (black triangles) and benign prostatic hyperplasia (BPH) (open triangles). A higher expression of IDO and of both cytokine genes was detected in  
PCa than in BPH tissue specimens (Mann–Whitney U test; IDO p < 0.001, IL-6 p < 0.0001). The 2−ΔΔCt method was used to compute  
fold changes in gene expression for both cytokines, setting GAPDH gene expression equal to 1. Values ≤107 were considered undetectable. (c,D) Fold changes  
in (c) IDO and (D) IL-6 gene expression in PCa tissue specimens were plotted against fold changes in IFN-γ (left panels) or TNF-α (right panels) gene expression  
in same specimens. A significant correlation was observed in all panels (Spearman rank correlation coefficient). (e) Gene expression of interferon gamma receptor  
1, 2 (IFNGR1 and 2) in PCa (black triangles) and BPH (open triangles). A significantly higher expression of IFNGR2 than of IFNGR1 in both BPH and PCa tissue 
specimens was observed (Mann–Whitney U test, p < 0.0001). IFNGR1 gene was significantly more expressed in PCa than in BPH (Mann–Whitney U test, 
p < 0.0001). The 2−ΔΔCt method was used to compute fold changes in gene expression in both receptors, setting GAPDH gene expression equal to 1. Values ≤107 
were considered undetectable. (F) Gene expression of tumor necrosis factor receptor 1 in PCa (black triangles) and BPH (open triangles). A significantly higher 
expression of the receptor was observed in PCa than in BPH tissue specimens (Mann–Whitney U test, p < 0.01). The 2−ΔΔCt method was used to compute  
fold changes in gene expression in both receptors, setting GAPDH gene expression equal to 1. Values ≤107 were considered undetectable.
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gene expression, but it did not impact on RFS. Indeed, IL-6 has 
been reported to contribute to the onset of castration-resistant 
PCa by activating alternative pathways involved in cancer survival 
and proliferation and by inducing androgen receptor overexpres-
sion in tumor cells (43). However, although IL-6 plasma levels 
have been suggested to predict severe prognosis (44–46), targeted 
treatments with therapeutic monoclonal antibodies have proved 
ineffective (47, 48).
Our results delineate a scenario where tumor cells may produce 
IDO, promoting the generation of an immune-suppressive micro-
environment upon stimulation by pro-inflammatory cyto kines, 
mainly IFN-γ. Therefore, while IDO would not “per  se” induce 
PCa, it might favor its progression. Indeed, pro-inflammatory 
cytokines are also produced in conditions unrelated to neoplastic 
transformation. Interestingly, however, the involvement of IFN-γ 
in the development of prostate inflammation, such as prostatitis, 
is debated. Seminal plasma from patients with chronic prostatitis 
(CP)/chronic pelvic pain syndrome show significantly higher levels 
of TNF-α and IL-1β when compared with those from healthy 
subjects (49), while no involvement of IFN-γ has been reported 
(50, 51). Hence, the inflammatory status in CP appears to be mainly 
due to the involvement of TNF-α and the IL-1β/IL-6 axis (52). Our 
data suggest that TNF-α marginally contributes to modulate IDO 
gene expression patterns and enzymatic activity (39, 40).
FigUre 6 | Indoleamine 2,3-dioxygenase (IDO) tumor-specific expression is a strong prognostic factor for biochemical recurrence (BR) in prostate cancer (PCa).  
(a) Receiver operating characteristic (ROC) curve analysis was used to evaluate the prognostic relevance of IDO gene expression. The area under the curve for 
recurrence-free survival (RFS) was 0.78 (95% CI, 0.67–0.88%) with an optimal cutoff level of 9.83 × 10−4 to dichotomize the patients into IDOhigh and IDOlow groups 
(specificity 78%, sensitivity 67%). (B) Kaplan–Meier estimates of RFS stratified by the established cutoff for IDO gene expression in PCa tissue specimens (IDO 
9.83 × 10−4). The survival analysis was based on time of BR (RFS with a median survival of 29 months; 95% CI, 22–36%; p < 0.0001, two-sided log rank test). (c) 
IDO gene expression in PCa tissue specimens was higher in BR-positive than in BR-negative patients (p < 0.001, Mann–Whitney U test), with a clear association 
between IDO gene levels and evidence of BR (prostate-specific antigen ≥ 0.1 ng/ml) (Pearson χ2 test).
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Clarification of molecular mechanisms underlying inflam-
mation-induced immune suppression might increase our ability 
to monitor the progression of PCa from a slow-growing, organ-
confined tumor to a highly invasive, and castration-resistant 
malignancy. Our data from urine sediment of men undergoing 
first time fine needle biopsy for PCa diagnosis show that patients 
with elevated IDO gene expression levels are at high risk of harbor-
ing a clinically relevant form of PCa and have a higher probability 
of relapsing after prostatectomy. Despite the limited number of 
subjects screened, the strength of this pilot study is represented 
by its high sensitivity. None of the subjects found positive for the 
presence of PCa showed IDO gene expression level below the 
optimal cutoff level of 0.0015, as defined by ROC to dichotomize 
the patients into PCa positive and PCa negative (PPV 100%, no 
false negative). In addition, two patients negative for PCa with 
IDO gene expression levels in urine below the optimal cutoff of 
0.0015 showed light inflammatory foci compatible with low-grade 
inflammation, as observed in biopsy material at histological level.
TaBle 5 | Distribution of clinical–pathological characteristics, in cancer sorted 
according to indoleamine 2,3-dioxygenase (IDO) or interleukin (IL)-6 gene 
expression levels.
Factors
characteristics iDOhigh, 
n = 26
iDOlow, 
n = 71
p-Value il-6high, 
n = 47
il-6low, 
n = 50
p-Valuea
Psa at diagnosis
<10 ng/mL 16 51 1 36 31 0.02
>10 ng/mL 6 20 7 19
Missing 0 4 4 0
Tumor stage
<pT3 5 16 1 13 7 0.2
>pT3 15 49 30 35
Missing 3 9 4 8
gleason score
≤7 (3 + 4) 9 25 0.6 21 13 0.06
≥7 (4 + 3) 13 50 26 37
Missing 0 0 0 0
aTwo-sided Fisher’s exact test.
TaBle 4 | Multivariate Cox regression analysis of the risk of biochemical 
recurrence (BR) associated with indoleamine 2,3-dioxygenase (IDO) gene 
expression level stratification adjusted for tumor stage (>3 vs ≥3) and Gleason 
score (≥6 vs ≥7).
Variable Parameter hr 95% ci p-Value
IDO gene expression IDOhigh vs. IDOlow 2.97 1.22–7.24 0.002
Gleason score ≥5–6 vs. ≤ 7–9 1.25 0.47–3.3 0.7
Tumor stage pT ≥ 3 vs. pT < 3 1.51 0.41–5.61 0.5
HR, hazard ratio.
All p-values were two-sided.
TaBle 3 | Univariate Cox regression analysis of the risk of biochemical 
recurrence associated with indoleamine 2,3-dioxygenase (IDO) and interleukin 
(IL)-6 gene expression.
Variable Parameter hr 95% ci p-Value
IDO gene expression IDOhigh vs. IDOlow 3.11 1.3–7.41 <0.01
IL-6 gene expression IL-6high vs. IL-6low 0.87 0.39–1.96 0.7
HR, hazard ratio.
All p-values were two-sided.
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FigUre 7 | Indoleamine 2,3-dioxygenase (IDO) gene expression in urine sediments of individuals at risk of developing prostate cancer (PCa). IDO relative gene 
expression was analyzed in urine sediments from patients collected without previous manipulation of the prostate. (a) Definition of the thresholds for IDO 
mRNA for the probability of having PCa. The area under the curve (AUC) for the presence/absence of PCa was 0.93 (95% CI, 0.84–1.03%) with an optimal 
cutoff level of 0.0015 to dichotomize the patients into PCa positive and PCa negative (specificity 100%, sensitivity 75%). (B) Definition of the thresholds for IDO 
mRNA for the probability of having a clinically relevant (GS ≥ 7) than an indolent (GS ≤ 6) PCa. GS was evaluated from the biopsy or after prostatectomy, when 
available. The AUC for indolent/aggressive PCa was 0.84 (95% CI, 0.66–1%) with an optimal cutoff level of 0.0095 (specificity 89%, sensitivity 80%). (c) Cutoff 
a (≤0.0015), assignment to biopsy for the risk of having PCa (NPV = 100%, PPV = 82%). Cutoff b (≥0.0096), assignment to biopsy for the risk of having 
clinically relevant PCa (NPV 83%, PPV 88%). A value of 0.0479 (black square) represents the risk of having biochemical recurrence within 5 years from 
prostatectomy.
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This novel screening approach based on the IDO mRNA levels 
in urine could offer innovative guiding tools for patient manage-
ment thereby helping to avoid overtreatment. Further more, it 
would reduce the number of individuals undergoing prostate 
biopsy, as dictated by the low-sensitive PSA test. In addition, the 
test is quick, cost-effective, and it does not require DRE/prostate 
massage for reliable read-out in the urine sediment.
Limitations of our work should be acknowledged. In particular, 
our study largely relies on gene expression analysis and we could 
not address specific protein detection in clinical specimens. While 
gene expression does not always accurately reflect protein levels 
due to post-translational regulation, major obstacles for cytokine 
detection by immunohistochemistry are represented by the low 
sensitivity of available reagents and the frequently diffuse stain-
ing. In contrast, qRT-PCR is straightforward and allows detection 
of the expression of multiple cytokine genes from same specimen 
(53, 54). On a similar line, IDO protein detection is challenging 
since most specific commercial reagents are characterized by a 
relatively low sensitivity. Therefore, target protein is usually only 
observed in the presence of high levels of gene expression, as 
described in a previous report (9). However, our data indicate 
that tryptophan/kynurenine ratios are dramatically decreased 
in supernatants of cytokine-stimulated PCa cells, consistent 
with the production of functionally active enzyme (Figure 3C). 
Furthermore, most interestingly, recent studies, taking advantage 
of newly developed, non-commercially available reagents, clearly 
indicate that IDO protein expression is detectable in tumor cells 
in 20% of clinical PCa specimens (55).
On the other hand, while correlations between the expression 
of the genes under investigation and clinical course were revealed 
by our study, mechanistic aspects remain largely unclear and war-
rant further research taking advantage of updated experimental 
models and of the availability more effective reagents.
Analysis of larger cohorts of patients will also be needed to vali-
date the clinical relevance of our data. Interestingly, the analysis of 
a larger cohort of about 500 samples, although provisional (TCGA; 
www.cbioportal.org), is in contrast with our finding concerning 
the association between high-IDO expression and survival of PCa. 
However, a critical requirement will be represented by a strict 
standardization of patient treatment and sample collection. Indeed, 
TCGA databases are generated upon evaluation of specimens from 
more heterogeneous cohorts of patients, undergoing a variety of 
different therapeutic procedures. Cases considered in our report 
were all from patients treated by the same group of urologists 
according to standardized procedures, including indications and 
timing for surgery and follow-up. Moreover, our gene expression 
data were analyzed by using specific ROC curves deriving from the 
combined analysis of qRT-PCR tests performed in a single lab and 
clinical results. In addition, TCGA data were obtained by RNA seq, 
a less sensitive technique, when compared with qRT-PCR.
A major problem in PCa treatment is represented by the 
individuation of patients requiring more aggressive therapeutic 
approaches, while avoiding overtreatment of the others. Therefore, 
the characterization of predictive PCa markers is of paramount 
clinical importance. Within this context, our results identify IDO 
as a predictor of poor prognosis in PCa, and the corresponding 
protein as a potential therapeutic target.
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FigUre s1 | Prognostic value of IL-6 gene expression in tumor samples.  
(a) Receiver operating characteristic (ROC) analysis to calculate the prognostic 
value of IL-6. The area under the curve (AUC) for recurrence-free survival (RFS) 
was 0.51 (95% CI, 0.37–0.65%) with no evidence for a prognostic potential.  
(B) Kaplan–Meier estimates of RFS stratified by an arbitrary cutoff (50th percentile) 
for IL-6 gene expression in PCa tissue specimens. The survival analysis was based 
on the time of BR. The estimated rate of 5-year RFS was 53% (95% CI, 48–58%; 
SE 2.7%) for IL-6high patients and 50% (95% CI, 44–55%; SE 3.03%; p = 0.8, 
two-sided log rank test) for IL-6low patients. (c) IL-6 gene expression in PCa tissue 
specimens was not significantly higher in BR-positive than in BR-negative patients 
(p = ns, Mann–Whitney U test). In addition, no association between IL-6 gene 
levels and evidence of BR (PSA ≥ 0.1 ng/ml) was documented (Pearson χ2 test).
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